Access cutting-edge twin; pregnancy, affecting fetus or newborn treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Boston location
Preparing your pre-screening questions…
Access twin; pregnancy, affecting fetus or newborn specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related twin; pregnancy, affecting fetus or newborn treatment provided free
Check if you qualify for this twin; pregnancy, affecting fetus or newborn clinical trial in Boston, MA
No-Cost Study Care
Local to Boston
Convenient for MA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Optimal diagnostic management and underlying pathophysiological mechanisms of selective fetal growth restriction (sFGR) in monochorionic diamniotic (MCDA) twin pregnancies have not been fully clarified. The current diagnostic classification system based on three different umbilical artery flow patterns has no increasing scale of severity and the predictive value is limited. Since there is no treatment available for sFGR, predicting fetal deterioration is key in preventing single or double fetal demise. Outcome prediction is furthermore important in the selection of cases that will be offered selective reduction (to provide the larger twin with better prospects), as well as determining monitor frequency and possible hospital admission. As outcome prediction is clinically challenging, patient counselling is too, and parents often encounter a great deal of uncertainty during the pregnancy. Furthermore, little is known about the brain development of sFGR children (both during pregnancy and after birth). Moreover, the psychological impact of an sFGR pregnancy of the future parent)s) has not been studied before. The impact of these factors should be taken into account during patient counseling, which is currently not the case. By our knowledge, this is the first international, multicenter, prospective cohort study on that will address the abovementioned questions and knowledge gaps in MCDA pregnancies complicated by selective fetal growth restriction.
Sponsor: Leiden University Medical Center
Yes, this clinical trial (NCT05952583) has an active research site in Boston, MA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for twin; pregnancy, affecting fetus or newborn treatment options in Boston, MA, this clinical trial (NCT05952583) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced twin; pregnancy, affecting fetus or newborn specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all twin; pregnancy, affecting fetus or newborn clinical trials near you to find additional studies recruiting in your area.
See all atrial fibrillation clinical trials recruiting in Boston — not just this study.
Browse Atrial Fibrillation Trials in Boston →